These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 38753770)

  • 41. DNA vaccine molecular adjuvants SP-D-BAFF and SP-D-APRIL enhance anti-gp120 immune response and increase HIV-1 neutralizing antibody titers.
    Gupta S; Clark ES; Termini JM; Boucher J; Kanagavelu S; LeBranche CC; Abraham S; Montefiori DC; Khan WN; Stone GW
    J Virol; 2015 Apr; 89(8):4158-69. PubMed ID: 25631080
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Hyperglycosylated stable core immunogens designed to present the CD4 binding site are preferentially recognized by broadly neutralizing antibodies.
    Ingale J; Tran K; Kong L; Dey B; McKee K; Schief W; Kwong PD; Mascola JR; Wyatt RT
    J Virol; 2014 Dec; 88(24):14002-16. PubMed ID: 25253346
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A Rare Mutation in an Infant-Derived HIV-1 Envelope Glycoprotein Alters Interprotomer Stability and Susceptibility to Broadly Neutralizing Antibodies Targeting the Trimer Apex.
    Mishra N; Sharma S; Dobhal A; Kumar S; Chawla H; Singh R; Das BK; Kabra SK; Lodha R; Luthra K
    J Virol; 2020 Sep; 94(19):. PubMed ID: 32669335
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ontogeny-based immunogens for the induction of V2-directed HIV broadly neutralizing antibodies.
    Moore PL; Gorman J; Doria-Rose NA; Morris L
    Immunol Rev; 2017 Jan; 275(1):217-229. PubMed ID: 28133797
    [TBL] [Abstract][Full Text] [Related]  

  • 45. B cells from knock-in mice expressing broadly neutralizing HIV antibody b12 carry an innocuous B cell receptor responsive to HIV vaccine candidates.
    Ota T; Doyle-Cooper C; Cooper AB; Doores KJ; Aoki-Ota M; Le K; Schief WR; Wyatt RT; Burton DR; Nemazee D
    J Immunol; 2013 Sep; 191(6):3179-85. PubMed ID: 23940273
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Precursor Frequency and Affinity Determine B Cell Competitive Fitness in Germinal Centers, Tested with Germline-Targeting HIV Vaccine Immunogens.
    Abbott RK; Lee JH; Menis S; Skog P; Rossi M; Ota T; Kulp DW; Bhullar D; Kalyuzhniy O; Havenar-Daughton C; Schief WR; Nemazee D; Crotty S
    Immunity; 2018 Jan; 48(1):133-146.e6. PubMed ID: 29287996
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Innate immune recognition of glycans targets HIV nanoparticle immunogens to germinal centers.
    Tokatlian T; Read BJ; Jones CA; Kulp DW; Menis S; Chang JYH; Steichen JM; Kumari S; Allen JD; Dane EL; Liguori A; Sangesland M; Lingwood D; Crispin M; Schief WR; Irvine DJ
    Science; 2019 Feb; 363(6427):649-654. PubMed ID: 30573546
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Designing boosting immunogens for HIV-1 vaccine development.
    Liu Q
    Cell Host Microbe; 2024 May; 32(5):632-634. PubMed ID: 38723601
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Live rubella vectors can express native HIV envelope glycoproteins targeted by broadly neutralizing antibodies and prime the immune response to an envelope protein boost.
    Virnik K; Nesti E; Dail C; Scanlan A; Medvedev A; Vassell R; McGuire AT; Stamatatos L; Berkower I
    Vaccine; 2018 Aug; 36(34):5166-5172. PubMed ID: 30037665
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.
    Patil S; Kumar R; Deshpande S; Samal S; Shrivastava T; Boliar S; Bansal M; Chaudhary NK; Srikrishnan AK; Murugavel KG; Solomon S; Simek M; Koff WC; Goyal R; Chakrabarti BK; Bhattacharya J
    J Virol; 2016 Jan; 90(7):3446-57. PubMed ID: 26763999
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cooperation between Strain-Specific and Broadly Neutralizing Responses Limited Viral Escape and Prolonged the Exposure of the Broadly Neutralizing Epitope.
    Anthony C; York T; Bekker V; Matten D; Selhorst P; Ferreria RC; Garrett NJ; Karim SSA; Morris L; Wood NT; Moore PL; Williamson C
    J Virol; 2017 Sep; 91(18):. PubMed ID: 28679760
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Multiplexed CRISPR/CAS9-mediated engineering of pre-clinical mouse models bearing native human B cell receptors.
    Wang X; Ray R; Kratochvil S; Melzi E; Lin YC; Giguere S; Xu L; Warner J; Cheon D; Liguori A; Groschel B; Phelps N; Adachi Y; Tingle R; Wu L; Crotty S; Kirsch KH; Nair U; Schief WR; Batista FD
    EMBO J; 2021 Jan; 40(2):e105926. PubMed ID: 33258500
    [TBL] [Abstract][Full Text] [Related]  

  • 53. GP120: target for neutralizing HIV-1 antibodies.
    Pantophlet R; Burton DR
    Annu Rev Immunol; 2006; 24():739-69. PubMed ID: 16551265
    [TBL] [Abstract][Full Text] [Related]  

  • 54. B cell clonal lineage alterations upon recombinant HIV-1 envelope immunization of rhesus macaques.
    Yacoob C; Lange MD; Cohen K; Lathia K; Feng J; Glenn J; Carbonetti S; Oliver B; Vigdorovich V; Sather DN; Stamatatos L
    PLoS Pathog; 2018 Jun; 14(6):e1007120. PubMed ID: 29933399
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Induction of Identical IgG HIV-1 Envelope Epitope Recognition Patterns After Initial HIVIS-DNA/MVA-CMDR Immunization and a Late MVA-CMDR Boost.
    Joachim A; Ahmed MIM; Pollakis G; Rogers L; Hoffmann VS; Munseri P; Aboud S; Lyamuya EF; Bakari M; Robb ML; Wahren B; Sandstrom E; Nilsson C; Biberfeld G; Geldmacher C; Held K
    Front Immunol; 2020; 11():719. PubMed ID: 32411138
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Progress in HIV vaccine development.
    Hsu DC; O'Connell RJ
    Hum Vaccin Immunother; 2017 May; 13(5):1018-1030. PubMed ID: 28281871
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Murine Antibody Responses to Cleaved Soluble HIV-1 Envelope Trimers Are Highly Restricted in Specificity.
    Hu JK; Crampton JC; Cupo A; Ketas T; van Gils MJ; Sliepen K; de Taeye SW; Sok D; Ozorowski G; Deresa I; Stanfield R; Ward AB; Burton DR; Klasse PJ; Sanders RW; Moore JP; Crotty S
    J Virol; 2015 Oct; 89(20):10383-98. PubMed ID: 26246566
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The Envelope-Based Fusion Antigen GP120C14K Forming Hexamer-Like Structures Triggers T Cell and Neutralizing Antibody Responses Against HIV-1.
    Raman SC; Mejías-Pérez E; Gomez CE; García-Arriaza J; Perdiguero B; Vijayan A; Pérez-Ruiz M; Cuervo A; Santiago C; Sorzano COS; Sánchez-Corzo C; Moog C; Burger JA; Schorcht A; Sanders RW; Carrascosa JL; Esteban M
    Front Immunol; 2019; 10():2793. PubMed ID: 31867001
    [TBL] [Abstract][Full Text] [Related]  

  • 59. An adenovirus-based HIV subtype B prime/boost vaccine regimen elicits antibodies mediating broad antibody-dependent cellular cytotoxicity against non-subtype B HIV strains.
    Gómez-Román VR; Florese RH; Peng B; Montefiori DC; Kalyanaraman VS; Venzon D; Srivastava I; Barnett SW; Robert-Guroff M
    J Acquir Immune Defic Syndr; 2006 Nov; 43(3):270-7. PubMed ID: 16940858
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Inference of the HIV-1 VRC01 Antibody Lineage Unmutated Common Ancestor Reveals Alternative Pathways to Overcome a Key Glycan Barrier.
    Bonsignori M; Scott E; Wiehe K; Easterhoff D; Alam SM; Hwang KK; Cooper M; Xia SM; Zhang R; Montefiori DC; Henderson R; Nie X; Kelsoe G; Moody MA; Chen X; Joyce MG; Kwong PD; Connors M; Mascola JR; McGuire AT; Stamatatos L; Medina-Ramírez M; Sanders RW; Saunders KO; Kepler TB; Haynes BF
    Immunity; 2018 Dec; 49(6):1162-1174.e8. PubMed ID: 30552024
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.